








OPEN ACCESS

# ForePass endoscopic bypass device for obesity and insulin resistance—metabolic treatment in a swine model

Giulia Angelini <sup>1</sup>, Manoel Galvao Neto <sup>2</sup>, Ivo Boskoski <sup>3</sup>, Maria Emiliana Caristo,<sup>4</sup> Sara Russo,<sup>1</sup> Luca Proto,<sup>5</sup> Elena Previti,<sup>1</sup> Lisa Olsson <sup>6</sup>, Hobby Aggarwal,<sup>7</sup> Samantha Pezzica,<sup>8</sup> Elisa Ferrari,<sup>8</sup> Vincenzo Bove,<sup>3</sup> Alfredo Genco,<sup>9</sup> Stefan Bornstein,<sup>10</sup> Valentina Tremaroli,<sup>11</sup> Amalia Gastaldelli,<sup>8</sup> Geltrude Mingrone <sup>1,5,12</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2023-331335>).

For numbered affiliations see end of article.

## Correspondence to

Dr Giulia Angelini, Università Cattolica del Sacro Cuore, Milano, Italy; [giulia.angelini@unicatt.it](mailto:giulia.angelini@unicatt.it)

GA, MGN and IB are joint first authors.

Received 17 October 2023  
Accepted 5 December 2023

## MESSAGE

Metabolic surgery (MS) causes long-lasting type 2 diabetes (T2D) remission through mechanisms that are beyond the mere weight loss being linked to the bypass of the upper gut. The ForePass device combines a channelled gastric balloon with an intestinal sleeve and aims at reducing simultaneously food intake and nutrients' absorption. In an experiment in four pigs, ForePass significantly lowered blood glucose and powerfully increased insulin-mediated glucose uptake, insulin clearance and reduced endogenous glucose production (EGP) over an observation period of 4 weeks without relevant complications. The weight gain was 79% lower than that observed in 4 sham-operated pigs. ForePass modified the composition of faecal microbiota raising the proportions of bacteria associated with metabolic health. Clinical studies are warranted.

## IN MORE DETAIL

A dramatic increase in T2D rates has been observed over the past 40 years.<sup>1</sup> T2D is closely associated with obesity, with over 80% of individuals with T2D having also obesity.<sup>1</sup>

Standard treatments for T2D and obesity include lifestyle interventions, medical therapy and MS. Nevertheless, lifestyle interventions and anti-obesity medications are only partially effective in determining long-term weight loss.<sup>2</sup> In contrast, MS has the potential to achieve long-lasting remission of T2D and reversal of several obesity complications.<sup>3</sup>

The ForePass device is an endoscopic alternative to MS that links the stomach to the jejunum via a gastric funnel connected to an intestinal sleeve. The balloon, which reduces the gastric volume by approximately 2/3, is traversed by a central channel that connects to the sleeve, which extends through the duodenum and proximal jejunum (figure 1A–C). Hence, ingested foods bypass the duodenum and proximal jejunum arriving directly into the mid-jejunum.

We hypothesised that the ForePass, which limits food intake and bypasses the upper gut, significantly improves glucose disposal and reduces weight gain in pigs relative to controls.

## WHAT IS ALREADY KNOWN ON THIS SUBJECT

⇒ Metabolic surgery (MS) is a highly effective treatment for obesity and type 2 diabetes, leading to sustained weight loss over time. Notably, MS can reverse several obesity-related comorbidities such as chronic inflammation, hypertension and non-alcoholic fatty liver diseases, including nonalcoholic steatohepatitis (NASH).

## WHAT ARE THE NEW FINDINGS

⇒ We showed that ForePass influences glucose kinetics, enhancing insulin-mediated whole-body glucose uptake, hepatic insulin sensitivity and insulin clearance. Moreover, ForePass modifies plasma metabolites and the variety and structure of faecal microbiota, increasing bacteria that beneficially impact glucose metabolism.

## HOW MIGHT IT IMPACT ON CLINICAL PRACTICE IN THE FORESEEABLE FUTURE

⇒ As a highly effective procedure, ForePass can be considered an incisionless alternative to traditional surgical procedures. ForePass can also be used for high-risk patients who are ineligible for MS, reject a surgical approach, prefer a bridge to MS, or as a complement or substitute to new anti-obesity and anti-diabetes medications. The use of ForePass may provide a much-needed alternative to MS.


To this end, we assessed glucose disposal, weight gain, metabolomics and faecal microbiota in eight pigs that were assigned to either Sham-operation (controls) or Forepass. Experimental procedures are shown in detail in the online supplemental appendix.

After 4 weeks, we observed a large reduction (79%) in the overall weight gain in part due to reduced food intake (22%) and in part to incomplete food digestion with increased faecal nutrient loss in the group with ForePass as compared with sham operation (table 1). We did not observe



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Angelini G, Galvao Neto M, Boskoski I, et al. *Gut* Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2023-331335



**Figure 1** Characteristics of the Forepass device. (A) The overall structure of the ForePass device, which is composed of a silicone gastric balloon and an expanded polytetrafluoroethylene (EPTFE) intestinal sleeve. A nitinol stent-like funnel, which traverses the balloon, connects to the sleeve. The transpyloric stent, coated by EPTFE, helps to improve device stability. (B) An endoscopic image of the proximal end of the ForePass device, including the inflated gastric balloon. The balloon's colour is due to methylene blue added to the saline solution used to inflate the device. (C) An X-ray fluoroscopy image of the ForePass device positioned in the stomach and proximal gut. The balloon component of the device is placed in the stomach, while the transpyloric stent and intestinal sleeve are located further down, past the pylorus.

macroscopical or microscopical lesions of the stomach and duodenal mucosa and submucosa.

We observed a significant decrease in plasma glucose, insulin and C-peptide levels in response to an intragastric glucose load (figure 2A–C) in ForePass. Accordingly, insulin sensitivity was significantly higher in the ForePass than in the sham group (table 1).

Intragastric glucose administration combined with U-<sup>13</sup>C-glucose and 6,6-deuterated glucose infusion resulted in a significantly lower glucose rate of appearance and disappearance in the ForePass than in the sham-operated group (figure 2D and E). Moreover, EGP was markedly suppressed with the ForePass (figure 2F) indicating a better hepatic insulin sensitivity.

**Table 1** Upper part: weight gain and food intake

Weight gain and food intake			
	Sham-Op	ForePass	P value
Basal weight (kg)	46.88±1.95	46.50±1.51	NS
Final weight (kg)	56.38±1.77	48.5±1.67	0.029
Food intake (kg/day)	2.00±0.01	1.77±0.04	0.028
Glucose minimal model			
	Sham-Op	ForePass	P value
$S_G \cdot 10^2$ (per min)	1.28±0.15	1.57±0.06	NS
$p \cdot 10^2$ (per min)	0.37±0.13	0.17±0.03	NS
$S_I \cdot 10^4$ (pm/min)	0.41±0.031	0.65±0.032	0.029
Stable isotope glucose kinetic			
	Sham-Op	ForePass	P value
EGP AUC -insulin AUC (μmol*pmol*min)	10.91±0.59	4.24±0.45	0.029
Insulin clearance (l/min)	2.61±0.009	2.96±0.06	0.029
$R_g$ AUC/insulin AUC (μmol/pmole*min)	0.024±0.003	0.039±0.004	0.029

Upper part: weight gain and food intake. art: basal, final weight and food intake. Middle part: minimal model analysis of glucose, insulin and C-peptide time courses following glucose administration via gastric gavage after Sham-Operation or ForePass. Lower part: stable isotope glucose kinetics. Data are expressed as mean±SEM.

$S_G$ , glucose effectiveness;  $p$ , minimal model parameter;  $S_I$ , insulin sensitivity; AUC, area under the curve; EGP, endogenous glucose production;  $R_g$ , rate of glucose disappearance.


Accordingly, we observed a higher hepatic insulin-sensitivity and insulin clearance as well as higher whole-body insulin-mediated glucose uptake in the ForePass versus the sham group (table 1).

To gain further insight into the mechanisms responsible for the improvement of insulin sensitivity following the ForePass implant, we performed polar metabolite analysis using GC/MS/MS. Figure 2G shows that the first two components of the principal component analysis explain 85.8% of the variance in plasma metabolites that significantly differ between sham-operation and Forepass. As observed in other studies testing markedly reduced energy intake,<sup>4,5</sup> we found increased circulating levels of amino acids and their metabolites in pigs with ForePass as compared with sham-operated animals (figure 2H, online supplemental table 1, online supplemental figure 1). Among amino acids, we found a surge of branched chain amino acids, valine, isoleucine and leucine, which are essential amino acids provided only with food. In agreement with the reduction of EGP, we observed a decrease in gluconeogenesis precursors with ForePass. Specifically, alanine, glutamine and glycine, but also lactate, which contributes from 7%<sup>6</sup> to 18%<sup>7</sup> to plasma glucose levels after an overnight fast.

To understand how caloric restriction and upper gut bypass could affect gut microbiota composition, we profiled the V4 region of the 16S rRNA gene in faecal samples. Faecal microbiota beta diversity, estimated both as weighted UniFrac (online supplemental figure 2A,  $p=0.026$ ,  $R^2=0.42$ ) and unweighted UniFrac (online supplemental figure 2B,  $p=0.023$ ,  $R^2=0.32$ ), was strongly affected by the ForePass device, indicating an effect on dominant faecal taxa (online supplemental figure 2C). The abundance of the genera *Treponema* and *Prevotella* decreased, while *Akkermansia*, *Christensenellaceae* R-7 group, *Bifidobacterium* and the Archaea *Methanobrevibacter* significantly increased (online supplemental figure 3A–F). The taxa increased with ForePass correlated significantly with the reduction of the area under the curve of EGP and insulin and with fasting C-peptide (online supplemental figure 4).

## COMMENTS

Our study shows that the ForePass device reduces body weight gain by 79% in rapidly growing pigs due to reduced food intake and increased faecal energy loss. Glucose absorption was also



**Figure 2** Metabolic shifts after ForePass. (A–C) Time courses and areas under the curve (AUCs) of blood glucose (A), plasma insulin (B), and plasma C-peptide (C) during an intragastric glucose administration (75g) using a combination of ingested and infused stable isotopically labelled glucose tracers in both ForePass™ and sham-operated pigs (Sham-Op). (D–F) Time courses and AUCs of the rate of appearance of exogenous glucose (Ra) (D), glucose rate of disappearance (Rd) (E), and endogenous glucose production. (G) Principal component analysis explains 85.8% of the variance of metabolites that significantly differ between ForePass and Sham-operation. (H) Heat map of polar metabolites 4 weeks after the interventions. Data are presented as mean values $\pm$ SEM (n=4 pigs per group). Statistical significance values were calculated by Mann-Whitney U test and repeated measure analysis of variance were appropriate.

reduced by 67%. Whole-body and hepatic insulin sensitivity were significantly increased with consequent reduction of insulin secretion and improvement of insulin clearance.

Other endoscopic procedures, such as duodenal-jejunal bypass liner (DJBL) and duodenal mucosal resurfacing (DMR) have attempted to mimic the effects of MS on T2D and insulin

resistance. DJBL improves glycaemic control in people with T2D, with an average HbA1c reduction of 0.9% and a weight loss of 11.3 kg at 1-year follow-up as compared with controls.<sup>8</sup> However, in people with insulin resistance and T2D, DJBL does not suppress EGP.<sup>9</sup> DMR improves glycaemic control in T2D<sup>10</sup> likely via a weight-independent mechanism, since weight loss was not significant at 6-month follow-up.<sup>10</sup> In women with insulin resistance, obesity and polycystic ovary syndrome, DMR did not improve significantly hepatic insulin sensitivity as shown by the lack of EGP suppression at 6 months after the procedure.<sup>11</sup> With due precaution when comparing human and swine data, ForePass significantly reduces EGP showing its beneficial effect in improving hepatic insulin resistance and potential in the treatment of both T2D and non-alcoholic fatty liver disease, where EGP is a key element.<sup>12</sup> Moreover, ForePass reduces major gluconeogenic substrates and, consequently, gluconeogenesis.

ForePass had an effect not only on glucose homeostasis but also on the composition of gut microbiota. The literature provides evidence that the gut microbiota has a substantial impact on metabolism and can modulate various aspects of the metabolic syndrome beyond obesity, including insulin resistance and glycaemic control.<sup>13,14</sup> In this study, we found that the ForePass device promotes the formation of a microbiota pattern that is known to be associated with a better metabolic outcome.

In conclusion, the ForePass device reduces glucose absorption and EGP, enhances whole-body insulin-mediated glucose uptake and hepatic insulin sensitivity with increased insulin clearance, reduces gluconeogenic substrates and improves the abundance and composition of faecal microbiota promoting a configuration that positively affects glucose metabolism. ForePass is an endoscopic procedure that, contrary to MS, is completely reversible. It could be used for those hesitant to undergo MS, high-risk patients who are ineligible for MS, as a bridge to bariatric surgery or MS, as well as a complement or substitute to new anti-obesity and anti-diabetic medications for these lifelong diseases.

#### Author affiliations

<sup>1</sup>Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy

<sup>2</sup>Bariatric Endoscopy department of Mohak Bariatric and Robotic Center, Sri Aurobindo Medical College, Indore, India, India

<sup>3</sup>Digestive Endoscopy Unit, Digestive Endoscopy Unit. Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, Rome, Italy

<sup>4</sup>Università Cattolica del Sacro Cuore, Rome, Italy

<sup>5</sup>Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy

<sup>6</sup>The Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

<sup>7</sup>Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden

<sup>8</sup>CNR Institute of Clinical Physiology, Pisa, Italy

<sup>9</sup>Surgery, University of Rome La Sapienza, Rome, Italy

<sup>10</sup>Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany

<sup>11</sup>Department of Molecular and Clinical Medicine Goteborg, University of Gothenburg, Goteborg, Västra Götaland, Sweden

<sup>12</sup>Diabetes, King's College London School of Medical Education, London, UK

**Correction notice** This article has been corrected since it published Online First. The first affiliation has been corrected.

**Twitter** Manoel Galvao Neto @MPGN46 and Ivo Boskoski @ivoboskoski

**Acknowledgements** This study was partially supported by a research grant from Keyron (London, UK). It was executed independently of Keyron, which had no role in data collection, analysis, and interpretation, and writing of the research paper. We would like to thank Mrs. Anna Caprodossi, the Translational Cardiovascular Science Lab - FPG -UCSC and Fondazione Roma. We are grateful for financial support for gut microbiota analyses by IMI n. 875534 Stratification of Obese Phenotypes to Optimize Future Obesity Therapy (SOPHIA) and thank Manuela Krämer for processing the samples. The computations for gut microbiota profiling were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX through grant agreement no. 2018-05973.

**Contributors** GM and GA designed the study. MGN, IB, VB and AG performed the surgical procedures. GA, SR and LP carried out the study. LO, HA and VT performed gut microbiota analyses. AG and SS measured stable isotopes. EP did the statistics. GA, AG, GM, MEC, and VT wrote the first draft. All authors actively contributed to the definitive version. AG and GM are jointly supervised this work.

**Competing interests** GA reports consulting fees from Metadeq and GHP Scientific. IB reports consulting fees from Apollo, Endosurgery, AndoTools, Nitinotes, Erbe Elektromedizin, Boston Scientific, Cook Medical and Pentax Medical. MGN reports consulting fees from Apollo EndoSurgery, USGI and Keyron. He is also a Scientific Advisor of Keyron and Morphic Medical. VB reports consulting fees from Apollo EndoSurgery. GM reports consulting fees from Novo Nordisk, Fractyl, Recor. She is also Scientific Advisor of Keyron, Metadeq, GHP Scientific, and Jemyl. All other authors declare no competing interests.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Giulia Angelini <http://orcid.org/0000-0001-6753-745X>

Manoel Galvao Neto <http://orcid.org/0000-0003-4549-3606>

Ivo Boskoski <http://orcid.org/0000-0001-8194-2670>

Lisa Olsson <http://orcid.org/0000-0001-9730-1915>

Geltrude Mingrone <http://orcid.org/0000-0003-2021-528X>

#### REFERENCES

- Nianogo RA, Arah OA. Forecasting obesity and type 2 diabetes incidence and burden: the vila-obesity simulation model. *Front Public Health* 2022;10.
- Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet* 2015;386:964–73.
- Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. *Lancet* 2021;397:293–304.
- Duregon E, Fernandez ME, Martinez Romero J, et al. Prolonged fasting times reap greater geroprotective effects when combined with caloric restriction in adult female mice. *Cell Metab* 2023;35:1179–94.
- Steinhauser ML, Olenchok BA, O'Keefe J, et al. The circulating metabolome of human starvation. *JCI Insight* 2018;3.
- Jenssen T, Nurjhan N, Consoli A, et al. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. demonstration of hepatic Autoregulation without a change in plasma glucose concentration. *J Clin Invest* 1990;86:489–97.
- Consoli A, Nurjhan N, Reilly JJ, et al. Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans. *Am J Physiol* 1990;259(5 Pt 1):E677–84.
- Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. *Diabetes Care* 2018;41:1106–15.
- Miras AD, Herring R, Vusirikala A, et al. Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans. *Obes Sci Pract* 2017;3:95–8.
- Mingrone G, van Baar AC, Devière J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. *Gut* 2022;71:254–64.

- 11 Kaur V, Dimitriadis GK, Pérez-Pevida B, *et al.* Mechanisms of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovary syndrome. *Metabolism* 2021;125.
- 12 London A, Lundsgaard A-M, Kiens B, *et al.* The role of hepatic fat accumulation in glucose and insulin homeostasis-dysregulation by the liver. *J Clin Med* 2021;10:390.
- 13 Fan Y, Pedersen O. Gut Microbiota in human metabolic health and disease. *Nat Rev Microbiol* 2021;19:55–71.
- 14 Chakaroun RM, Olsson LM, Bäckhed F. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease. *Nat Rev Cardiol* 2023;20:217–35.